Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

NCT04391049 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT04391049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04391049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Lead sponsor
NRG Oncology
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 2, 2021
Completion date
October 6, 2029
Enrollment
16 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal adenocarcinoma, advanced gastroesophageal junction adenocarcinoma, clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iia esophageal adenocarcinoma ajcc v8, clinical stage iia gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iib esophageal adenocarcinoma ajcc v8, clinical stage iib gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ii esophageal adenocarcinoma ajcc v8, pathologic stage ii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iia esophageal adenocarcinoma ajcc v8, pathologic stage iia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iib esophageal adenocarcinoma ajcc v8, pathologic stage iib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iii esophageal adenocarcinoma ajcc v8, pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia esophageal adenocarcinoma ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib esophageal adenocarcinoma ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ii esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage ii gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib gastroesophageal junction adenocarcinoma ajcc v8, squamous cell cancer, squamous cell carcinoma, unresectable gastroesophageal junction adenocarcinoma